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Mifepristone, a Blocker of Glucocorticoid Receptors,
Promotes Photoreceptor Death
Marisa A. Cubilla, Vicente Bermu´dez, Melisa D. Marquioni Ramella, Toma´s P. Bachor,
and Angela M. Suburo
PURPOSE. Glucocorticoids are best known by their protective
effect on retinal photoreceptor damage. However, they could
also be involved in photoreceptor homeostasis under basal,
nonstressful conditions. Therefore, we aimed to study gluco-
corticoid-induced changes of survival-related molecules in male
mice retinas under standard illumination conditions (12 hours
light,  60 lux/12 h dark).
METHODS. Male Balb-c mice were injected with dexamethasone
(DEX), a selective glucocorticoid receptor a (GRa) agonist, its
antagonist mifepristone (MFP), or both drugs (DþM) at noon. A
group of mice was subjected to surgical adrenalectomy (AdrX).
Retinas were studied by histology, immunohistochemistry,
TUNEL procedure, and Western blotting at different periods
after pharmacological or surgical intervention (6 hours, 48
hours, or 7 days).
RESULTS. The antiapoptotic molecule Bcl-XL significantly
increased 6 hours after DEX injection. By contrast, this
molecule could no longer be found after MFP injection. At
the same time, high levels of cleaved caspase-3 (CC-3) and Bax
appeared in retinal extracts, and TUNELþ nuclei selectively
showed in the outer nuclear layer (ONL). After MFP, retinal
extracts also contained phosphorylated histone H2AX (p-
H2AX), a marker of DNA breakage and repair. Loss of ONL
nuclear rows and decrease of rhodopsin levels were evident 7
days after MFP administration. These changes were minimized
when DEX was given together with MFP (DþM). In the absence
of MFP, DEX increased Bcl-XL in every retinal layer, with a
marked intensification in photoreceptor inner segments.
Numerous TUNELþ nuclei rapidly appeared in the ONL after
AdrX.
CONCLUSIONS. A single dose of MFP induced selective photo-
receptor damage in the absence of other environmental
stressors. Because damage was prevented by DEX, and was
reproduced by AdrX, our findings suggest that glucocorti-
coids play a critical role in photoreceptor survival. (Invest
Ophthalmol Vis Sci. 2013;54:313–322) DOI:10.1167/
iovs.12-10014
Glucocorticoids are widely used in various ophthalmolog-ical conditions,1 such as traumatic optic neuropathy,2
diabetic macular edema,3 retinal vein occlusion,4 cystoid
macular edema,5,6 noninfectious uveitis,7 radiation retinopa-
thy,8 and even for AMD in the combination known as triple
therapy.9 Evidence for the role of these steroids in photore-
ceptor protection derives from experimental retinal degener-
ation studies. In the light-induced degeneration model in
rodents, glucocorticoid-mediated protection has been associ-
ated to a decrease of lipid peroxidation10 or to suppression of
the activator protein 1 (AP-1) upregulation.11 However,
glucocorticoids can prevent AP-1 increases without avoiding
photoreceptor damage.12 Additionally, glucocorticoid treat-
ment increases photoreceptor survival after laser-induced
damage.13,14 Intravitreal fluocinolone acetonide protects pho-
toreceptors in Royal College of Surgeons (RCS) rats and
simultaneously reduces microglial activation.15
On the other hand, we have previously shown that
mifepristone (MFP, RU 486), an antagonist of glucocorticoid
a receptors (GRa), aggravates light-induced retinal damage.16
In this model, MFP administration increases cleaved caspase-3
(CC-3) in photoreceptor nuclei and rhodopsin (RHO) deple-
tion. Dexamethasone (DEX), a well-known GRa ligand,1
prevents light-induced CC-3 activation and RHO reduction,
both in control and MFP-treated mice.16 Preliminary experi-
ments showed that MFP induced selective death of murine
photoreceptors under standard illumination conditions (12
hours light,  60 lux/12 h dark), without detectable injury to
other retinal cells (Cubilla MA, et al. IOVS 2011;52: ARVO E-
Abstract 5462). Hence, we have now explored the effects of
MFP and adrenalectomy (AdrX) on photoreceptor survival in
the absence of known environmental stressors.
Several mechanisms have been proposed to explain the role
of glucocorticoids as key signals in the balance between
survival and death of diverse cell phenotypes.17,18 Glucocor-
ticoid-dependent death or survival is directly associated with
the selective expression of the short or long isoforms of Bcl-X
(Bcl-XS or Bcl-XL), which are pro- and antiapoptotic, respec-
tively.17 Cells resistant to glucocorticoid-induced apoptosis,
such as some cancer cells19,20 and fibroblasts,21 show
increased production of Bcl-XL. In the hippocampus, where
they induce cell death, glucocorticoids increase the ratio of the
proapoptotic molecule Bax relative to the antiapoptotic
molecule Bcl-XL.
22 Therefore, we used the ratio Bcl-XL/Bax to
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Statement for the Use of Animals in Ophthalmic and Vision Research.
We used male BALB/c mice, between 35 to 45 days of age. One of the
experiments was repeated in C57Bl6/J mice of the same age and sex
(see below). Mice were bred under standard cycling illumination
conditions (12 hours light,  60 lux/12 h dark). Experiments began at
12 AM, with a 24-hour period of complete darkness for all mice. At
noon on the next day, we randomly separated them into the different
experimental groups and returned them to the standard light cycle.
These animals were euthanatized 6 hours, or 2 or 7 days after
pharmacological intervention.
Pharmacological Interventions
We used MFP (Sigma-Aldrich, St. Louis, MO) in propylene glycol and
dexamethasone disodium phosphate (DEX; Sidus, Buenos Aires,
Argentina) in NaCl 0.9% solution as subcutaneous injections. Mice
received a single initial dose of 10 mg/kg MFP or 4 mg/kg/d DEX during
2 consecutive days. Some mice were given different doses, as specified
in the text or figure captions. For combined treatment (DþM), mice
received both drugs simultaneously but in different injections.
Nontreated controls received the same volumes of both vehicles
(VHCs). MFP-treated mice received a glucose supplement (1 mL of 5%
glucose, intraperitoneal; Fidex, Buenos Aires, Argentina) to prevent a
stress-like condition arising in these animals.
Adrenalectomy
Mice were anesthetized with desfluorane and surgery was performed
according to conventional procedures.23 We ablated both adrenals
together with the perirenal fat pad, and confirmed extraction
microscopically. The abdominal wall and the skin were sutured
separately. Sham animals were anesthetized and had a skin incision.
All animals received antibiotics (20 mg/kg/d ceftazidime; Fada Pharma,
Buenos Aires, Argentina) during 2 days. A 0.9% NaCl solution replaced
drinking water for adrenalectomy (AdrX) mice.
Immunohistochemical and TUNEL Procedures
After deep anesthesia, animals were perfused transcardially with 4 g/
100 mL paraformaldehyde in a phosphate buffer 0.1 M, pH 7.3.
Dorsolateral regions of the eyeball were ink-labeled before enucle-
ation. After lens removal, fixation continued during 1 hour. Sucrose
solutions of increasing concentrations (5%–20% in phosphate buffer
0.01 M) provided cryoprotection. Eye pairs (one control and one
experimental) were embedded in the optimal cutting temperature
compound (OCT; Biopack, Buenos Aires, Argentina) and frozen in
N2 cooled acetone. Eyes were sectioned through para-equatorial
planes; thus, each section crossed the temporal and nasal retinas.
Cryosections (9-lm thick) were mounted on gelatinized slides and,
after dehydration and delipidization, they were incubated with
primary antibodies (Table 1). Detection was made with biotinylated
secondary antibodies, followed by the avidin-biotin-peroxidase
complex (Elite Vector; Vector Laboratories, Burlingame, CA) that
was developed with a nickel-enhanced procedure.24 In negative
controls, diluent replaced the primary antibody.
Alternatively, 6-lm sections collected on positive slides (Instru-
mental Pasteur, Argentina) were assayed for DNA fragmentation with
the FragEL system (DNA Fragmentation Detection Kit, Fluorescent-TdT
Enzyme, Calbiochem; Merck KGaA, Darmstadt, Germany). Labeled
nuclei were scored by a blinded operator.
Evaluation of the Outer Nuclear Layer in Neutral
Red–Stained Sections
Eyes were embedded as before and seriate sections were stained with
0.2% Neutral Red (Sigma-Aldrich) for 8 minutes. The thickness of the
outer nuclear layer (ONL) was evaluated in sections through the optic
nerve head (ONH), using digital images obtained with a Nikon-DS
digital camera (Nikon, Microlat, Argentina) at 34 magnification with
2560 3 1920 pixels.25 Measurements were made at 250-lm intervals
from the ONH with the tools of Adobe Photoshop CS4 Extended
(Adobe, San Jose, CA).
Western Blots
At the end of the experiment, animals underwent 30 minutes of
complete darkness to allow full separation of the RPE. Euthanasia and
enucleation took place under dim red light. Retinas (6 per experimen-
tal point) were extracted in a buffer containing 5 mM Tris-HCl with 2
mM MgCl2, 2 mM EDTA, 65 mM NaCl, 1% Triton X-100, and protease
inhibitor cocktail (Sigma-Aldrich). After measuring protein concentra-
tion with the Bradford protein assay (Sigma-Aldrich), samples (30 lg
protein per lane) were separated by SDS-PAGE (BioRAD, Canton, MA).
They were transferred (120 v, 120 minutes) to nitrocellulose filters
(Hybon-P; Amersham Pharmacia Biotech, Piscataway, NJ) using
standard techniques. Membranes were incubated with primary
antibodies (Table 1), followed by appropriate biotinylated secondary
antibodies and extravidin-peroxidase (Sigma-Aldrich). Immunoreactive
bands were developed with an enhanced chemiluminescence detec-
tion kit (ECL; Amersham Pharmacia Biotech). Outcomes were pixels
per band, measured with Adobe Photoshop CS4 Extended (Adobe),
using automatic adjustment and measurement sequences. Labeling of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) bands confirmed
equal transfer to the membranes.
Statistics
Quantitative data are presented as average 6 SE, with an indication
of the number of samples for each experiment in the text or the
corresponding figure legends. Student’s t-test or ANOVA, comple-
mented by Tukey’s test for multiple comparisons, were calculated
with GraphPad Prism 5.00 for Windows (GraphPad Software, San
Diego CA; www.graphpad.com). Letters shared by two or more
groups indicate lack of significant statistical difference between
those groups.
RESULTS
CC-3 Under Basal Illumination Conditions
Control retinas did not show any CC-3 protein. By contrast,
injection of 4, 10, or 30 mg/kg MFP provoked the appearance
of increasing levels of CC-3 just 6 hours after MFP administra-
TABLE 1. Primary Antibodies Used in Immunohistochemistry and Western Blots
Antibody Type Source
GAPDH Mouse monoclonal (6C5, sc-32233) Santa Cruz Biotechnology, Inc., Santa Cruz, CA
Bcl-X Rabbit polyclonal (B9304) Sigma-Aldrich, St. Louis, MO
Bax Rabbit polyclonal (sc-493) Santa Cruz Biotechnology, Inc.
CC-3 Rabbit polyclonal (9661) Cell Signaling Technology, Inc., Danvers, MN
p-H2AX Rabbit monoclonal (ab2893) Abcam, Inc., Cambridge, MA
RHO Mouse monoclonal (B6-30) J. Nathans (School of Medicine, Johns Hopkins University, Baltimore, MD)
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tion (Fig. 1A). Therefore, in further experimental work we
used a single 10-mg/kg injection of MFP at the beginning of the
experiment.
We then compared DEX and MFP effects at 6 and 48 hours.
CC-3 was not found at any time in animals receiving VHC or
DEX, but high CC-3 levels appeared 6 or 48 hours after a single
MFP injection. Simultaneous administration of the agonist-
antagonist combination (DþM) partially prevented CC-3 rise at
6 hours, but not at 48 hours (Fig. 1B).
Since appearance of the apoptosis executor CC-3 could
reflect an exacerbation of the high sensitivity of Balb-c mice
to environmental light, we repeated this experiment in
C57Bl6/J mice, which are resistant to light injury. MFP also
determined the appearance of CC-3 in this strain, and
simultaneous DEX administration prevented CC-3 rise at 6
hours (not shown).
Effects of DEX and MFP on Bcl-XL and Bax
Bcl-XL increased 6 and 48 hours after DEX treatment, but this
antiapoptotic molecule was not detected in extracts from MFP-
or DþM–treated mice (Table 2). A higher DEX dose (10 mg/kg),
which induced a higher Bcl-XL increase (11,720 6 180 pixels,
n¼ 4), did not prevent this effect of MFP (Fig. 2).
Control retinas displayed Bcl-XL immunoreactivity in all
their strata. In the outer retina, immunoreactivity was
concentrated at the inner segments (Fig. 3A). Strong immuno-
staining also appeared in the ganglion cell layer (GCL) and
inner nuclear layer (INL). DEX treatment increased immuno-
reactivity, particularly at the level of the inner segments (Fig.
3B). By contrast, Bcl-XL immunoreactivity completely disap-
peared after MFP injection (Fig. 3C). Only weak immunoreac-
tivity showed in DþM retinas, mainly at the level of the GCL
(Fig. 3D). Similar staining patterns appeared after 6 and 48
hours of treatment.
Bax and Bcl-XL showed opposite responses (Table 2). Bax
increased 7- to 10-fold above control values at 6 and 48 hours
after a single MFP injection (P < 0.001). Large Bax increases
also occurred in mice receiving the combined DþM. Statisti-
cally significant differences between MFP and DþM appeared at
6 hours (P < 0.01), but were no longer present after 48 hours.
In animals receiving MFP, with or without DEX, the Bcl-XL/Bax
ratios approached 0.
DNA Damage and Repair
Neither control nor DEX-treated retinas showed TUNELþ
nuclei. Only a few TUNELþ nuclei could be seen 2 hours after
MFP administration, but large numbers were present after 6
and 48 hours. TUNELþ nuclei were selectively found in the
ONL. Quantitative analysis did not detect differences in
TUNELþ nuclei density between 6 or 48 hours. DþM retinas
did not show TUNELþ nuclei at 2 or 6 hours but displayed
some positive nuclei after 48 hours (Fig. 4).
Fragmented DNA can be repaired by complex mechanisms
involving the phosphorylation of histone 2AX. The phosphor-
ylated isoform (p-H2AX) accumulates near to DNA double-
strand breaks and serves as a marker of DNA damage and
repair.26 Control and DEX-treated retinas showed no p-H2AX.
By contrast, p-H2AX appeared 6 hours after MFP administra-
tion, and its levels were even higher 48 hours after
pharmacological intervention. Combined DþM administration
did not avoid appearance of p-H2AX, but levels were lower
than with MFP alone (Fig. 5).
FIGURE 1. Levels of CC-3 protein in retinal extracts after different pharmacological interventions. In all figures, a shared letter indicates lack of
significant statistical differences. (A) Increasing CC-3 levels appeared 6 hours after administration of increasing MFP doses, from 4 to 30 mg/kg
(ANOVA, P < 0.0001; n¼ 3, P < 0.01 for all comparisons). Bottom: representative proteinograms showing CC-3 and GAPDH bands from the same
extracts. (B) Levels of CC-3 appearing after DEX (4 mg/kg/d), MFP (10 mg/kg, single dose) or their combination, DþM. After 6 and 48 hours, CC-3
protein was present only in mice treated with MFP or DþM. Co-administration of DEX reduced CC-3 levels at 6 hours (P < 0.001) but did not
prevent their increase at 48 hours. Below, CC-3 and GAPDH bands from a representative WB.
FIGURE 2. A proteinogram showing Bcl-XL changes 48 hours after
administration of MFP with two different DEX doses: D4, (4 mg/kg, as
in previous experiments) and D10 (10 mg/kg). Although DEX (4 mg/
kg) increased Bcl-XL control values, no bands were observed in extracts
from MFP, D4þM, or D10þM retinas. See also Table 2.
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Long-Term Effects of a Single MFP Injection
As an index of photoreceptor demise, we measured changes
in the thickness of the ONL using seriate sections stained
with Neutral Red. Initially, a blinded operator made a
systematic inspection comparing the thickness of the ONL
with that of the INL. In control retinas, the ONL was always
wider than the INL. We considered that damage existed when
the ONL was equal to or thinner than the INL (Fig. 6). These
findings are shown as a normal cylindrical projection of the
retina, with meridians mapping to equidistant vertical lines
(Fig. 7A). No structural alterations appeared in retinas fixed 6
hours after the pharmacological interventions. After 48
hours, the ONL of MFP and DþM retinas showed low-grade
lesions that occupied 18.2% 6 1.7% of the total area in MFP
retinas, and only 4.9% 6 2.5% of the total area in DþM retinas
(t-test, P < 0.005). Control (VHC injection) and DEX retinas
showed no damage.
To test for delayed MFP effects on photoreceptor survival,
mice were fixed 7 days after pharmacological intervention.
As before, control and DEX retinas presented no detectable
damage. In MFP retinas, 48.9% 6 3.0% of the total retinal area
showed some degree of photoreceptor nuclei loss. Affected
areas in MFP retinas were larger than in DþM retinas (t-test, P
< 0.002). Severe lesions appeared only in 7-day MFP retinas
(Fig. 6D), where they occupied almost half of the affected
area (42.8% 6 1.7%). This value was statistically different
from 0 (t-test for one sample, P < 0.002). In addition, we
measured the thickness of the ONL in equatorial sections
(Fig. 7B). Graphs indicated a large decrease in MFP retinas,
most evident in the temporal hemisphere. As shown by areas
under the curve (AUCs), there was a significant decrease of
the ONL thickness in MFP-treated mice (Table 3). We did not
find significant differences between the AUCs of control and
DþM retinas; however, the thickness at the first point of the
temporal hemisphere was significantly lower in DþM than in
control or MFP retinas, consistent with the small change
detected in our qualitative evaluation.
Two days after administration of DEX, MFP, or their
combination, RHO levels were not statistically different from
those found in control retinas (Fig. 8A); however, after 7 days,
MFP retinas showed a third of the RHO protein found in
control (VHC) retinas. Levels in mice subjected to DþM
treatment were not statistically different from those in mice
that had received a single MFP injection (Fig. 8B).
FIGURE 3. Bcl-XL immunoreactivity in cryosections from retinas fixed 6 hours after pharmacological interventions. (A) In control retinas, Bcl-XL
immunoreactivity concentrated in the GCL, the INL, and the inner segments (Is). (B) Inner segment immunoreactivity increased after DEX
treatment. (C) No immunoreactivity appeared after MFP injection. (D) After the combined treatment, weak Bcl-XL immunoreactivity remained in
the GCL and the INL. Scale bar, 40 lm (A–D).
TABLE 2. Levels of Bax and Bcl-XL Proteins 6 and 48 Hours after Pharmacological Intervention
Time Protein VHC DEX MFP DþM
6 hours Bcl-XL 5223 6 163 7574 6 420* ND* ND*
Bax 1933 6 401 3659 6 603 14,670 6 108* 10,720 6 51*
Bcl-XL/Bax 2.70 2.07 0.007 0.009
48 hours Bcl-XL 6902 6 433 9946 6 415* ND* ND*
Bax 1987 6 415 4285 6 728 20,080 6 3,033* 18,600 6 2,542*
Bcl-XL/Bax 3.47 2.73 0.005 0.005
Area of Western blot bands (pixels, mean 6 SE, n ¼ 4) was compared with ANOVA, followed by Tukey’s test. ND, not detected.
* Differences with VHC values were statistically significant (P < 0.001).
TABLE 3. Thickness of the ONL 7 Days after Pharmacological Intervention
Measure VHC DEX MFP DþM
Total AUC, lm2 188 6 2 186 6 6 127 6 4* 181 6 5
Temporal AUC, lm2 92 6 1 91 6 1 49 6 3* 88 6 3
Thickness at first temporal point, lm 46 6 1 46 6 1 27 6 1* 33 6 2* †
The AUCs representing the ONL thickness were compared by one-way ANOVA followed by Tukey’s test. Values are given as mean 6 SE (n¼ 4).
* Differences with VHC values were statistically significant, P < 0.001.
† Difference with MFP value was statistically significant, P < 0.05.
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Adrenalectomy
Retinas from AdrX and sham-operated mice were studied 6 and
48 hours after surgery. Retinas from sham-operated mice never
showed TUNELþ nuclei. On the contrary, all AdrX retinas
showed TUNELþ nuclei that selectively appeared in the ONL.
Damaged nuclei were more numerous at 48 hours than at 6
hours after AdrX. TUNEL staining pattern at 48 hours resembled
that observed 48 hours after MFP administration (Fig. 9).
DISCUSSION
Glucocorticoids are involved in most cell- and tissue-signaling
networks of the organism. They can affect every organ system
and regulate important survival responses, such as the
behavioral and physical response to stress and disease, the
inflammatory reaction, the process of sleep, growth, and
reproduction.27 Within the retina, glucocorticoids are well
known by their protective effects after retinal light damage28;
however, they also modulate the electroretinogram of non-
injured retinas,29,30 suggesting that they could also be
important for nonstressed retinas.
Glucocorticoids and Glucocorticoid Receptors in
Cell Death and Survival
Understanding the role of glucocorticoids in the retina, as in
other neural and non-neural tissues, requires a brief description
of the complexity of glucocorticoid receptor (GR) isoforms.27,31
Alternative splicing of the GR gene transcript generates two C-
terminal glucocorticoid receptor isoforms: GRa and GR. In
addition, this gene has several initiation sites, giving rise to
various isoforms of different length. In the bound state, GRa
translocates to the nucleus and binds to glucocorticoid response
elements (GREs). GRa may also inhibit key transcription factors,
such as nuclear factor-jB (NF-jB) and activator protein-1 (AP-
1).32 MFP is a partial agonist of GRa that allows nuclear
translocation of the receptor. The conformational change
triggered by association to MFP prevents binding of coactivators
and activates recruiting of corepressors.33 By contrast, GRb has
a unique ligand-binding domain that does not associate with
known glucocorticoids and behaves as a dominant negative
inhibitor of GRa.31 Some studies, however, suggest that GRb
FIGURE 4. (A–C) These composite images of para-equatorial retinal sections show the extent of TUNEL reactivity under different experimental
conditions. (A) Six hours after MFP injection, large numbers of TUNELþ nuclei appeared in both retinal hemispheres, nasal and temporal. (B) A
similar pattern of TUNELþ nuclei distribution showed 48 hours after MFP administration. (C) By contrast, 48 hours after DþM treatment, retinas
displayed a small amount of TUNELþ nuclei. Scale bars, 50 lm. (D) Quantitative analysis of TUNELþ nuclei density showed that retinas displayed the
same high density 6 and 48 hours after MFP injections. No TUNELþ nuclei appeared 6 hours after DþM injections, whereas a very low amount was
present 48 hours after the combined treatment. Density is expressed as nuclei per 250 lm of ONL (mean6 SE, from 3 retinas, 4 fields per section, n
¼ 12).
FIGURE 5. (A) Quantitative analysis of p-H2AX Western blots from
retinal extracts obtained 6 and 48 hours after pharmacological
intervention (n ¼ 3; ANOVA, P < 0.0001). Differences between
columns displaying the same letter were not statistically significant. No
p-H2AX was detected in control retinas (VHC), or in those from DEX-
treated mice. High levels appeared 6 hours after MFP injection (MFP
versus VHC o DEX, P < 0.001) and were partially prevented by
simultaneous DEX treatment (DþM versus MFP, P < 0.001). Higher
levels appeared in MFP and DþM retinas after 48 hours (MFP-6 vs. 48, P
< 0.001; DþM-6 vs. 48, P < 0.01). However, DþM at 48 hours was not
statistically different from MFP at 6 hours. (B) p-H2AX and GAPDH
proteinograms at 6 and 48 hours after pharmacological interventions.
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FIGURE 6. (A) A schematic drawing of a retinal section shows the points where we evaluated the ONL. (B) This retinal section, stained with Neutral
Red, corresponds to a mouse that received MFP 7 days before fixation. Numbers indicate the ONL rating from 0 (no damage) to 3 (severe damage).
(C) Images of the ONL ranked according to damage: 0, the ONL was thicker than the INL; 1, the ONL had the same thickness as the INL; 2, the ONL
was thinner than the INL; 3, only 1 to 3 nuclear rows remained in the ONL.
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isoforms might have intrinsic, GRa-independent, transcriptional
activity, possibly modulated by MFP binding.34
Evidence demonstrating the role of glucocorticoids in cell
survival and death is plentiful, particularly since glucocorti-
coid-dependent apoptosis is one of the mainstays of cancer
treatment. Their role in brain and retina has multiple facets, as
different neuronal phenotypes respond in opposite fash-
ion.35–38 The diverse roles of GRa on cell death and survival
depend on differential modulation of pro- and antiapoptotic
Bcl-2 family members.39 As previously stated, the prosurvival
effect of glucocorticoids is associated with increased expres-
sion of Bcl-XL,
17 the antiapoptotic molecule preferentially
expressed by adult central and retinal neurons.40 Evidence
indicates that Bcl-XL blocks Bax translocation to the mitochon-
dria41; thus, we evaluated DEX and MFP effects on these two
molecules.
Early Effects of DEX and MFP
Briefly, DEX significantly increased retinal Bcl-XL, as it occurs in
other tissues where glucocorticoids have antiapoptotic ac-
tions.18 A similar pattern appeared after 48 hours, although Bcl-
XL levels in DEX-treated animals were higher than after 6
hours. Photoreceptor inner segments, which contain a large
amount of mitochondria, showed the largest DEX-induced
increase of Bcl-XL immunoreactivity. Thus, Bcl-XL modulation
might have some primary influence on photoreceptor func-
tions. DEX also induced a slight increase of Bax, reflected in a
decreasing tendency of the Bcl-XL/Bax ratio in DEX-treated
retinas. No evidence of cell death or DNA repair was found in
control or DEX-treated retinas.
By contrast, MFP depleted Bcl-XL and at the same time
increased Bax levels, with Bcl-XL/Bax ratios approaching 0,
both at 6 and 48 hours. Photoreceptor injury was a very early
phenomenon, with the first ONL TUNELþ nuclei appearing
within 2 hours of MFP administration. At 6 and 48 hours after
MFP injection, TUNELþ nuclei consistently appeared in the
ONL of every retinal area, excepting the marginal zone. They
were not found in any other retinal layer. Rising levels of CC-3
provided further evidence of retinal injury. Damage was
accompanied by the activation of DNA repair mechanisms, as
denoted by the accumulation of p-H2AX.26
Structural damage of the ONL only became apparent 48
hours after MFP injection, with significant loss of photorecep-
tor nuclei showing 7 days after the single MFP injection. Repair
mechanisms might explain why photoreceptor loss at 7 days
was mainly restricted to the temporal hemisphere, whereas in
early stages, TUNELþ nuclei appeared in every retinal region. At
48 hours, ONL lesions were very small and localized in the
central retina. This explains why no decrease of RHO appeared
at this stage. By contrast, a significant decrease of RHO levels
appeared after 7 days, when photoreceptors had disappeared
in approximately half of the retina. The course of RHO changes
suggests that lesion of the outer segments would be a
secondary effect of photoreceptor death and not its cause, as
in light-induced retinal degeneration.16,28
Interactions between DEX and MFP
Combined administration of DEX and MFP (DþM) significantly
reduced retinal damage. DEX prevented increase of CC-3 levels at
6 hours but not at 48 hours after DþM injections. Similarly,
animals subjected to DþM treatment did not show TUNELþ
nuclei at 6 hours, but displayed a considerable amount of injured
nuclei after 48 hours, in spite of the second DEX injection.
Accumulation of p-H2AX followed the same pattern, with levels
increasing during the second day of the combined treatment. p-
H2AX buildup is proportional to the amount of DNA breaks,42
indicating that DEX prevented MFP-induced double-strand
breaks. Reduction of caspase-3 activation would reduce DNA
FIGURE 8. (A) Bars indicate levels of RHO protein 2 days after pharmacological intervention. No significant changes were detected (n ¼ 3). (B)
Seven days after treatment, MFP retinas showed reduced RHO protein levels (MFP versus DEX or VHC, P < 0.001; n¼ 3). A significant reduction
also appeared in DþM retinas (DþM versus DEX or VHC, P < 0.001; n¼ 3), but RHO levels were higher in DþM than in MFP mice (P < 0.01; n¼3).
FIGURE 7. (A) These four graphs correspond to normal cylindrical projections of retinas at 2 and 7 days of treatment with MFP and DþM. Degree of
damage at each point is indicated by a color code (right lower corner). Grade 1 lesions appeared after 2 days, the affected area being significantly
larger after MFP than after DþM injections. Lesions of grades 2 and 3 were present only in MFP retinas 7 days after treatment. At this time, DþM
retinas only showed grade 1 lesions. (B) Measurement of the ONL thickness in sections passing through the optic nerve head showed a normal
pattern in control animals (VHC). After MFP injection, the temporal hemisphere presented a large lesion. Only a small lesion was detected 7 days
after DþM injections (statistical comparisons are described in Table 3).
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fragmentation, but glucocorticoids could also interact directly
with p53.43 This might be an important antiapoptotic mecha-
nism in the retina, as DEX prevented photoreceptor death
without improving the MFP-induced Bcl-XL depletion.
In spite of the TUNEL and CC-3 increases during the second
day of the experiment, mice subjected to the combined
treatment showed little ONL damage at 7 days after MFP
injection; however, their RHO levels resembled those of MFP-
treated animals.
These findings might be explained by the long half-life of
MFP.44 On the other hand, they might reflect other effects of
this molecule, perhaps dependent on GRb isoforms.45,46 MFP
also antagonizes progesterone receptors,47 which are also
involved in Bcl-XL upregulation
48,49 and have a role in
photoreceptor protection.50,51 Our present findings, however,
suggest that glucocorticoid signaling is required for photore-
ceptor survival. We used male mice, where progesterone levels
are low,52 and survival was promoted by DEX, a selective
ligand of GRa, with very low affinity for mineralocorticoid and
progesterone receptors.1,53 Most important, we induced
selective photoreceptor death by AdrX, supporting the
involvement of glucocorticoids in photoreceptor maintenance.
MFP and Photoreceptor Death
Present findings indicate that MFP is a potent and selective
toxin for murine photoreceptors. This effect cannot be
explained by the dose, because we used a single 10-mg/kg
injection. By contrast, higher amounts (20–100 mg/kg) and
longer treatments are often reported in the literature.54–57
Lack of Bcl-XL increases photoreceptor vulnerability to
some stressors, but would not be a direct cause of
photoreceptor damage.58 MFP induced disappearance of Bcl-
XL in all retinal cell phenotypes; however, only photoreceptors
were damaged after MFP administration. On the other hand,
photoreceptors are the highest oxygen-consuming cells in the
organism and are particularly susceptible to oxidative stress.59
This property could perhaps explain their extreme sensitivity
to MFP, as glucocorticoids are involved in the clearance of
oxidative damage in neurons.60
Main Conclusions
Both MFP and AdrX provoked selective damage of photore-
ceptor nuclei in male mice under standard illumination
conditions. DEX prevented damage, suggesting that adrenal
steroids might be essential for photoreceptor survival in a
normal environment.
MFP is currently approved in several countries for
termination of pregnancy, and has been recommended for
emergency contraception, leiomyomas, and endometriosis.61
Its use as an antidepressant and in central serous chorioretin-
opathy has also been proposed.62,63 Daily doses of 200 to 600
mg are recommended but, to our knowledge, visual adverse
effects have not been reported. Thus, massive photoreceptor
damage as we have seen in two different strains of mice
probably would not occur in humans; however, DNA
fragmentation could determine selective accumulation of
mutations in photoreceptor nuclei, perhaps enhancing degen-
erative phenomena produced by other causes.
On the other hand, confirmation of an essential role of
glucocorticoids (or other adrenal steroids) in photoreceptor
homeostasis, would support their use in combination with
more specific agents, for prevention or treatment of retinal
degenerations.
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